The Problem

The United Nations estimated that 303,000 women died from complications associated with pregnancy and childbirth in 2015. 99% of these deaths occurred in the developing world.

*A price too high to bear: The costs of maternal mortality to families and communities* documents the extraordinarily severe financial, economic and social impact of maternal death in Kenya. Of the 59 maternal deaths in the study, only 15 babies survived the first 60 days. In another study that reviewed the impact of maternal mortality over 25 years in Ethiopia, it was found that children whose mother dies within 42 days of their birth faced 46 times greater risk of dying within one month when compared to babies whose mothers survived. It is imperative that we continue to seek to reduce maternal mortality.

Postpartum hemorrhage (PPH) is responsible for approximately 10.8% of global maternal mortality (with prevalence across Africa averaging 25.7% and as high as 39.7% in one African region). The leading cause of PPH is uterine atony. Administration of an effective uterotonic immediately following the delivery of the baby is recommended by the WHO to prevent PPH resulting from uterine atony (failure of the uterus to contract).

Oxytocin, the WHO-recommended standard medicine administered for the prevention of PPH in women, is temperature-sensitive and requires sustained cold chain distribution and storage to ensure its quality. The quality, and therefore effectiveness, of uterotonics available in low income countries is often poor resulting in failure to prevent hemorrhage. The principle causes of poor quality in oxytocin are:

- sub-standard manufacturing and
- susceptibility to degradation due to heat exposure.

There is an unmet need for a low-cost, quality assured, heat-stable uterotonic to prevent postpartum hemorrhage in low income countries.

Heat-Stable Carbetocin Project

MSD for Mothers, the World Health Organization (WHO) and Ferring Pharmaceuticals are collaborating to provide access to a heat-stable formulation of the uterotonic carbetocin, a medicine used to prevent postpartum hemorrhage in women after childbirth.

The availability of a medicine that does not require refrigeration during transportation and storage, and can be kept at elevated temperatures for at least three years, has the potential to significantly improve the prevention and management of bleeding following childbirth in the many areas of the world where cold storage is difficult to achieve and maintain. This will help reduce maternal deaths in those areas.
A WHO-led multi-centre Phase III clinical study is comparing the effectiveness of Heat-Stable Carbetocin (HSC) and oxytocin (both delivered intramuscularly) in the prevention of postpartum hemorrhage and severe postpartum hemorrhage after vaginal births. The study, which will include approximately 30,000 women, is taking place in 10 countries: Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda, and the United Kingdom. Enrolment of subjects has passed 23,000 with the trial expected to be completed in Q3 2017.

If the results of the study are positive, the aim of the collaborating organizations is to provide access to Heat-Stable Carbetocin in the public sector of low income countries that have a high burden of maternal mortality, at an affordable and sustainable price.

Concept Foundation is contributing expertise in maternal health supplies for low income countries to the project.

Heat-Stable Carbetocin

Heat-Stable Carbetocin is a uterotonic medicine used for the prevention of postpartum hemorrhage.

A single 100µg dose of Heat-Stable Carbetocin is effective in preventing postpartum hemorrhage after caesarean section.

Heat-Stable Carbetocin remains stable (retains potency) for at least 36 months (3 years) in hot and humid climatic conditions. It does not require cold-chain transport or storage.

Carbetocin, developed and manufactured by Ferring Pharmaceuticals since 1997, has been used for the prevention of PPH in over 8.5 million women in over 80 countries worldwide, primarily after caesarean section deliveries (7 countries have also approved it for use following vaginal deliveries).

The heat stable formulation, Heat-Stable Carbetocin, has recently been introduced into 27 countries, including Australia, Mexico and across Europe.
Comparison with Oxytocin

<table>
<thead>
<tr>
<th>Heat Stable Carbetocin</th>
<th>Oxytocin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heat-stable for at least 3 years at 30°C (ICH Zone IV</td>
<td>Rapidly degrades when exposed to heat.</td>
</tr>
<tr>
<td>Stable – Hot/Humid Tropical Zone). Retains potency even</td>
<td></td>
</tr>
<tr>
<td>when exposed to heat for extended periods of time.</td>
<td></td>
</tr>
<tr>
<td>Does not require refrigeration.</td>
<td>Requires sustained cold-chain transport and storage.</td>
</tr>
<tr>
<td>The half-life of carbetocin is 40 minutes.</td>
<td>The half-life of oxytocin is 3-5 minutes.</td>
</tr>
<tr>
<td>Carbetocin produces rhythmic contractions lasting for up</td>
<td>The duration of effect of oxytocin is approximately 30</td>
</tr>
<tr>
<td>to 120 minutes.</td>
<td>minutes.</td>
</tr>
</tbody>
</table>

Global Engagement

Broad engagement across a wide variety of stakeholders is needed to ensure that women in low income countries have access to Heat-Stable Carbetocin. Normally, the introduction of a medicine into a market would entail large, expensive marketing campaigns. In this case, on successful completion of the WHO trial, low cost advocacy and community engagement will be necessary in order to ensure that HSC is available to the public sector in low income countries at an affordable price. Some of the changes that will be necessary in order for women to receive HSC to prevent postpartum hemorrhage include:

- Updating global guidelines on the recommended prevention and treatment of PPH
- Updating country and facility level guidelines on the prevention and treatment of PPH
- Including HSC in country formularies, essential medicines lists and registered drugs lists
- Country level registration and marketing approval for HSC
- Updating pre-service and in-service training programs for healthcare professionals including midwives, physicians and obstetricians on the correct use of HSC for PPH
- Including HSC in medicines procurement decisions
- Development of job aids and tools to ensure correct usage of HSC

Members of the global maternal health community can assist the project partners in achieving the goal of ensuring access to quality assured Heat-Stable Carbetocin in all low-income countries through engagement in advocacy, collaboration on community awareness activities and expert contributions.

Contacts

For further information on Heat-Stable Carbetocin for the prevention of postpartum hemorrhage or to contribute to the project, please contact:

**Concept Foundation** - Fiona Theunissen, Project Officer
fiona.theunissen@conceptfoundation.org

**MSD for Mothers** - Jeff Jacobs, Director Product Innovation & Market Access
jeffrey_jacobs@merck.com

**World Health Organization** - Mariana Widmer, Technical Officer
widmerm@who.int

**Ferring Pharmaceuticals** – Helen Gallagher, Senior Director Industry Affairs and Social Responsibility
helen.gallagher@ferring.com